Clinical trial
Antithymocyte Globulin and Cyclosporine in Treating Patients With…
NCT00004208 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00004208 |
|---|---|
| Title | Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome |
| Official title | Antithymocyte Globulin (ATG) and Cyclosporine (CSA) to Treat Patients With Myelodysplastic Syndrome (MDS). A Randomized Trial Comparing ATG + CSA With Best Supportive Care |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Behavioral, Drug |
| Interventions | ATG + CSA, Supportive care |
| Enrollment | 86 |
| Start date | Aug 1, 2000 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 11, 2015 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: